PreCursor-M+

Qualitative detection of promotor hypermethylation of 2 cervical cancer associated genes (FAM19A4andhsa-miR124-2) .Identify HPV positive women with high short-term progression to (pre) cancer.Special Features:Sample types:Bisulfite-converted DNA isolated from physician collected cervical specimens or self-collected vaginal specimensClinical performance - Long-term data:Most evaluated and validatedmethylation assayto identify HPV positive women with progressing cervical disease in direct need for colposcopy or other follow-up procedures1,2Demonstrating very high sensitivity for cervical cancer detection (95.0-100%) in HPV-positive cervical specimens2,3,4Longitudinal data: Thelong-term risk for cancer with a negative PreCursor-M+ is lower than with a negative cytology result; for CIN3 the long-term risk is similar as cytology5,6Flexible:Suitable for various sample types, including self-samples and common Liquid Based Cytology media typesCompatible with standard DNA extraction methodsReliable:Build-in check for sample quality ensuring reliable resultsPrecursor-M+ is a registered trademark of the legal manufacturer, Self-screen B.V., the Netherlands, and is distributed by Fujirebio Europe.